Story

WuXi Biologics Shares Rise Over 4% on Deal to Acquire Transcenta Facility

ENTHMSVIIDZHZH-TWJAKOHI
Aug 7, 20261 min read
WuXi Biologics Shares Rise Over 4% on Deal to Acquire Transcenta Facility
Text size
Background

Shares of WuXi Biologics, a global contract research, development, and manufacturing organization (CRDMO), surged in Hong Kong trading after the company announced a deal to acquire a biopharmaceutical facility from Transcenta Holding.

Market Reaction

On August 7, WuXi Biologics' stock (02269.HK) climbed 4.25% to close at HK$43.14, with a trading turnover of HK$368 million, as reported by Zhitong Finance APP. The stock price increase followed the morning announcement of the planned acquisition.

Deal Details

In a statement released via its official channels, WuXi Biologics confirmed it had reached an agreement to purchase Transcenta's process development and production base located in Hangzhou, China. The transaction is expected to be completed in the third quarter of 2026.

The facility is a significant addition to WuXi Biologics' infrastructure:

Sample IUX Markets – In-articleAd
  • It covers an area of over 10,000 square meters.
  • It is equipped with capabilities for process development, drug substance manufacturing, and drug product (fill-finish) services.

Strategic Rationale

The acquisition is intended to enhance WuXi Biologics' integrated, end-to-end service capabilities to meet growing client demand for development and commercial-scale projects. The company noted the expansion is necessary to support its increasing project pipeline.

"The acquisition further enhances WuXi Biologics' end-to-end service capabilities," said Dr. Chris Chen, CEO of WuXi Biologics, in the announcement. "As the number of projects and commercialization demand continue to grow, we will continue to respond to the diverse needs of our customers with high quality and high efficiency."

Read next

More on Stocks
Back to latest news

LATEST